PMID- 35711668
OWN - NLM
STAT- MEDLINE
DCOM- 20220620
LR  - 20220716
IS  - 2235-2988 (Electronic)
IS  - 2235-2988 (Linking)
VI  - 12
DP  - 2022
TI  - Gut Microbiota and Antidiabetic Drugs: Perspectives of Personalized Treatment in 
      Type 2 Diabetes Mellitus.
PG  - 853771
LID - 10.3389/fcimb.2022.853771 [doi]
LID - 853771
AB  - Alterations in the composition and function of the gut microbiota have been 
      reported in patients with type 2 diabetes mellitus (T2DM). Emerging studies show 
      that prescribed antidiabetic drugs distort the gut microbiota signature 
      associated with T2DM. Even more importantly, accumulated evidence provides 
      support for the notion that gut microbiota, in turn, mediates the efficacy and 
      safety of antidiabetic drugs. In this review, we highlight the current 
      state-of-the-art knowledge on the crosstalk and interactions between gut 
      microbiota and antidiabetic drugs, including metformin, alpha-glucosidase inhibitors, 
      glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, 
      sodium-glucose cotransporter 2 inhibitors, traditional Chinese medicines and 
      other antidiabetic drugs, as well as address corresponding microbial-based 
      therapeutics, aiming to provide novel preventative strategies and personalized 
      therapeutic targets in T2DM.
CI  - Copyright (c) 2022 Liu, Luo, Zhou and Sun.
FAU - Liu, Wenhui
AU  - Liu W
AD  - Department of Pharmacy, The Second Xiangya Hospital, Central South University, 
      Changsha, China.
AD  - Institute of Clinical Pharmacy, Central South University, Changsha, China.
FAU - Luo, Zhiying
AU  - Luo Z
AD  - Department of Pharmacy, The Second Xiangya Hospital, Central South University, 
      Changsha, China.
AD  - Institute of Clinical Pharmacy, Central South University, Changsha, China.
FAU - Zhou, Jiecan
AU  - Zhou J
AD  - Institute of Clinical Medicine, The First Affiliated Hospital, University of 
      South China, Hengyang, China.
FAU - Sun, Bao
AU  - Sun B
AD  - Department of Pharmacy, The Second Xiangya Hospital, Central South University, 
      Changsha, China.
AD  - Institute of Clinical Pharmacy, Central South University, Changsha, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20220531
PL  - Switzerland
TA  - Front Cell Infect Microbiol
JT  - Frontiers in cellular and infection microbiology
JID - 101585359
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Blood Glucose
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - *Gastrointestinal Microbiome
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology/therapeutic use
MH  - Precision Medicine
PMC - PMC9194476
OTO - NOTNLM
OT  - antidiabetic drugs
OT  - efficacy and safety
OT  - gut microbiota
OT  - personalized therapeutic targets
OT  - type 2 diabetes mellitus
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/06/18 06:00
MHDA- 2022/06/22 06:00
PMCR- 2022/01/01
CRDT- 2022/06/17 02:30
PHST- 2022/01/13 00:00 [received]
PHST- 2022/05/04 00:00 [accepted]
PHST- 2022/06/17 02:30 [entrez]
PHST- 2022/06/18 06:00 [pubmed]
PHST- 2022/06/22 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fcimb.2022.853771 [doi]
PST - epublish
SO  - Front Cell Infect Microbiol. 2022 May 31;12:853771. doi: 
      10.3389/fcimb.2022.853771. eCollection 2022.